IL124689A - Apoptosis induced by monoclonal antibody anti-her2 - Google Patents

Apoptosis induced by monoclonal antibody anti-her2

Info

Publication number
IL124689A
IL124689A IL12468996A IL12468996A IL124689A IL 124689 A IL124689 A IL 124689A IL 12468996 A IL12468996 A IL 12468996A IL 12468996 A IL12468996 A IL 12468996A IL 124689 A IL124689 A IL 124689A
Authority
IL
Israel
Prior art keywords
antibody
her2
monoclonal antibody
present
antibody anti
Prior art date
Application number
IL12468996A
Other languages
English (en)
Other versions
IL124689A0 (en
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24269821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL124689(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL124689A0 publication Critical patent/IL124689A0/xx
Publication of IL124689A publication Critical patent/IL124689A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL12468996A 1995-12-05 1996-12-04 Apoptosis induced by monoclonal antibody anti-her2 IL124689A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/568,072 US5783186A (en) 1995-12-05 1995-12-05 Antibody-induced apoptosis
PCT/US1996/019289 WO1997020858A1 (en) 1995-12-05 1996-12-04 Apoptosis induced by monoclonal antibody anti-her2

Publications (2)

Publication Number Publication Date
IL124689A0 IL124689A0 (en) 1998-12-06
IL124689A true IL124689A (en) 2003-03-12

Family

ID=24269821

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12468996A IL124689A (en) 1995-12-05 1996-12-04 Apoptosis induced by monoclonal antibody anti-her2

Country Status (14)

Country Link
US (5) US5783186A (de)
EP (3) EP2298816A3 (de)
JP (1) JP2002502230A (de)
AT (1) ATE251644T1 (de)
AU (1) AU723492B2 (de)
CA (1) CA2236913A1 (de)
DE (1) DE69630313T3 (de)
DK (2) DK0865448T4 (de)
ES (2) ES2208773T5 (de)
IL (1) IL124689A (de)
MX (1) MX9804358A (de)
PT (2) PT1375520E (de)
SI (2) SI1375520T1 (de)
WO (1) WO1997020858A1 (de)

Families Citing this family (238)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
DE69736806T3 (de) * 1996-03-27 2015-10-08 Genentech, Inc. ErbB3 ANTIKÖRPER
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
ATE233102T1 (de) * 1996-05-15 2003-03-15 Altarex Inc Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
KR20060079258A (ko) * 1996-10-18 2006-07-05 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
US6270980B1 (en) * 1997-06-05 2001-08-07 Idun Pharmaceuticals, Inc. Rapid methods for identifying modifiers of cellular apoptosis activity
HUP0003513A3 (en) * 1997-09-11 2004-05-28 Chugai Pharmaceutical Co Ltd Monoclonal antibody inducing apoptosis
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO1999048527A1 (en) * 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
FR2780062B1 (fr) * 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
EP1146789B1 (de) 1999-01-27 2009-03-18 Cornell Research Foundation, Inc. Behandlung von mit her-2/neu-überexprimierung einhergehendem krebs
AU4209300A (en) * 1999-04-06 2000-10-23 Genentech Inc. Use of erbb receptor ligands in treating diabetes
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BR0012196A (pt) 1999-06-25 2002-03-19 Genentech Inc Método de tratamento de um tumor em mamìferos através do uso de conjugados de maitansinóide e anticorpo receptor anti-erbb e artigo industrializado
ES2282120T3 (es) * 1999-06-25 2007-10-16 Genentech, Inc. Tratamiento del cancer de prostata con anticuerpos anti-erbb2.
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
US7041292B1 (en) * 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
KR20110008112A (ko) * 1999-08-27 2011-01-25 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7947496B2 (en) 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20040001789A1 (en) * 1999-10-08 2004-01-01 Young David S. F. Cytotoxicity mediation of cells evidencing surface expression of gp96 or precursors thereof
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20040105816A1 (en) * 1999-10-08 2004-06-03 Young David S. F. Cancerous disease modifying antibodies
US7252821B2 (en) * 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US6657048B2 (en) * 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US8048416B2 (en) 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20080124327A1 (en) * 1999-10-08 2008-05-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7419792B2 (en) * 1999-10-08 2008-09-02 Arius Research Inc. Laminin Receptor 1 Precursor Protein (37LRP) epitope delineated by an Hepatocellular carcinoma specific antibody
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US7256271B2 (en) 2003-01-21 2007-08-14 Arius Research Inc. Cancerous disease modifying antibodies
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US6794494B1 (en) 2003-04-14 2004-09-21 Arius Research, Inc. Cancerous disease modifying antibodies
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP1118334A1 (de) * 2000-01-11 2001-07-25 Aventis Behring Gesellschaft mit beschränkter Haftung Verfahren zur Herstellung von Konjugate zur Behändlung von Allergien und Autoimmunkrankheiten
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
EP1280923A2 (de) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, ein angehörige der menschlichen trypsin-familie, und dessen verwendungen
CA2407556C (en) * 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
EP1311675B1 (de) * 2000-08-22 2007-02-07 Agensys, Inc. Nukleinsäure und protein, genannt 158p1d7, für die behandlung und erkennung von blasenkrebs und anderen krebsarten
US7534429B2 (en) * 2000-11-29 2009-05-19 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7431923B2 (en) * 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US20060210474A1 (en) * 2000-11-29 2006-09-21 Young David S Cytotoxicity mediation of cells evidencing surface expression of CD63
US7442777B2 (en) * 2000-11-29 2008-10-28 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
AU2002249170B2 (en) * 2001-02-02 2007-02-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V Method for identifying functional nucleic acids
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
AU2003213606A1 (en) * 2002-03-01 2003-10-13 Exelixis, Inc. MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EP2289942B1 (de) * 2002-04-10 2013-07-31 Genentech, Inc. Anti-HER2 Antikörper-Varianten
US20050260208A1 (en) * 2002-04-11 2005-11-24 Altarex Medical Corp. Binding agents and their use in targeting tumor cells
WO2004008099A2 (en) 2002-07-15 2004-01-22 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
DK2314629T4 (da) * 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
WO2004048525A2 (en) * 2002-11-21 2004-06-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies
US7361342B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7488475B2 (en) 2003-01-21 2009-02-10 Arius Research, Inc. Antibody therapy of tumors
US7175846B2 (en) * 2003-01-21 2007-02-13 Arius Research Inc. Cancerous disease modifying antibodies
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US7468254B2 (en) * 2003-01-21 2008-12-23 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7195764B2 (en) 2003-04-14 2007-03-27 Arius Research Inc. Cancerous disease modifying antibodies
US7399835B2 (en) * 2004-02-26 2008-07-15 Arius Research Inc. Cancerous disease modifying antibodies
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US20050008649A1 (en) * 2003-06-02 2005-01-13 University Of Miami Chimeric molecules and methods of use
US20050232931A1 (en) * 2003-06-13 2005-10-20 Oncomax Acquisition Corp. Preparation and application of anti-tumor bifunctional fusion proteins
US20040254108A1 (en) * 2003-06-13 2004-12-16 Jing Ma Preparation and application of anti-tumor bifunctional fusion proteins
TWI476206B (zh) 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
US20050027106A1 (en) * 2003-07-28 2005-02-03 Young David S. F. Cancerous disease modifying antibodies
WO2005014618A2 (en) * 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
EP2478912B1 (de) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Konjugate von Auristatin mit gegen HER2- oder CD22-gerichtete Antikörper und deren therapeutische Verwendung
EP1737971B1 (de) 2004-01-20 2017-08-16 Merus N.V. Gemische bindender proteine
US7348413B2 (en) * 2004-02-26 2008-03-25 Arius Research Inc. Cancerous disease modifying antibodies
US20050255041A1 (en) * 2004-05-13 2005-11-17 Arius Research, Inc. Cancerous disease modifying antibodies
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
DK1771482T3 (da) * 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US7394210B2 (en) * 2004-09-29 2008-07-01 Tir Technology Lp System and method for controlling luminaires
CA2583230A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
EP1699826B1 (de) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
MX2007009566A (es) * 2005-02-09 2009-02-16 Genentech Inc Inhibicion de la difusion de la her2 con antagonistas de la metaloproteasa de matriz.
EP1850874B1 (de) * 2005-02-23 2013-10-16 Genentech, Inc. Verzögerung des krankheitsverlauf bei eierstockkrebspatienten durch pertuzumab
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7456259B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452979B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7456258B2 (en) 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452978B2 (en) 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
FR2895086B1 (fr) * 2005-12-16 2012-10-05 Lab Francais Du Fractionnement Potentialisation de l'apoptose par des anticorps monoclonaux
US20080213267A1 (en) * 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
JP2009528993A (ja) 2006-02-24 2009-08-13 アリアス リサーチ、インコーポレイテッド 癌様疾患修飾性抗体１４１２０５−０２
US20080305104A1 (en) * 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
EP1996699A4 (de) * 2006-02-24 2009-02-25 Arius Res Inc Antikörper, die krebserkrankungen modifizieren
US7420040B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
US20080089891A1 (en) * 2006-07-26 2008-04-17 Arius Research, Inc. Cancerous disease modifying antibodies
US8350011B2 (en) 2006-08-04 2013-01-08 Medimmune Limited Antibodies to ErbB2
AU2007321664A1 (en) * 2006-11-13 2008-05-22 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies
CA2668503A1 (en) * 2006-11-13 2008-05-22 F. Hoffmann-La Roche Ag Cancerous disease modifying antibodies 180706-01
WO2008058379A1 (en) * 2006-11-13 2008-05-22 Arius Research Inc. Cancerous disease modifying antibodies
US20080206133A1 (en) * 2007-01-23 2008-08-28 Young David S F Cancerous Disease Modifying Antibodies
US8003761B2 (en) 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
EP2126055A4 (de) * 2007-03-26 2011-11-23 Hoffmann La Roche Mittels hybridoma-zelllinie ar51a630.3 hergestellter tumormodifizierender antikörper 010207-01
CN101688183A (zh) * 2007-05-07 2010-03-31 霍夫曼-拉罗奇有限公司 减轻癌性疾病的抗体
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US9551033B2 (en) * 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) * 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
PE20090943A1 (es) 2007-07-16 2009-08-05 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
EP2176295B1 (de) 2007-07-16 2014-11-19 Genentech, Inc. Humanisierte anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
CA2710680C (en) * 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US20090191197A1 (en) * 2008-01-28 2009-07-30 Young David S F Cancerous disease modifying antibodies
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
KR101607346B1 (ko) 2008-01-31 2016-03-29 제넨테크, 인크. 항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
WO2009124381A1 (en) * 2008-04-10 2009-10-15 F. Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
EP2291406A4 (de) * 2008-05-19 2012-12-12 Takeda Pharmaceutical Zytotoxischer monoklonaler antikörper gegen krebs
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2313437A1 (de) * 2008-07-17 2011-04-27 Takeda Pharmaceutical Company Limited Antikörper, die krebserkrankungen modifizieren
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010051502A2 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
WO2011004899A1 (en) 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2478110B1 (de) 2009-09-16 2016-01-06 Immunomedics, Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011130580A1 (en) 2010-04-15 2011-10-20 Alper Biotech, Llc Monoclonal antibodies against her2 antigens, and uses therefor
US9328024B2 (en) 2010-04-29 2016-05-03 The Regents Of The University Of California Application of high toughness, low viscosity nano-molecular resin for reinforcing pothole patching materials in asphalt and concrete base pavement
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2407487A1 (de) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispezifische modulare Antikörper
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
EP2647706B1 (de) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur wiederholten bindung an mehrere antigenmoleküle
KR101574864B1 (ko) 2010-12-21 2015-12-11 에프. 호프만-라 로슈 아게 이소폼이 농축된 항체 제제 및 그의 제조 방법
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
EP2546268A1 (de) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalisierendes Immunglobulin
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
EP2751285B2 (de) 2011-08-31 2020-04-01 Genentech, Inc. Methode zur bestimmung der empfindlichkeit eines tumors für egfr kinase-inhibitoren
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
IL301603A (en) 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
BR112014012979A2 (pt) 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
TWI606063B (zh) 2012-08-23 2017-11-21 艾澤西公司 結合至１５８ｐ１ｄ７蛋白之抗體藥物結合物（ａｄｃ）
IL238323B2 (en) 2012-10-30 2023-11-01 Esperance Pharmaceuticals Inc Antibody/drug conjugates and methods of use
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US10611837B2 (en) * 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
US11058768B2 (en) 2014-04-16 2021-07-13 Biocon Ltd. Stable protein formulations comprising a molar excess of sorbitol
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
HUE049175T2 (hu) 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
EP3303373B1 (de) 2015-05-30 2020-04-08 Molecular Templates, Inc. Deimmunisierte shigatoxin-a-untereinheitsgerüste und zellgerichtete moleküle damit
CN107787331B (zh) 2015-06-17 2022-01-11 豪夫迈·罗氏有限公司 抗her2抗体和使用方法
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
AU2016306209B2 (en) 2015-08-07 2023-07-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific CAR T-cells for solid tumor targeting
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
EP3494991A4 (de) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Zusammensetzung zur vorbeugung oder behandlung von erkrankungen im zusammenhang mit il-8
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
EP3567049A4 (de) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation Chimärer antigenrezeptor und natürliche killerzellen zur expression davon
TW202508629A (zh) 2017-01-17 2025-03-01 美商建南德克公司 皮下her2抗體調配物
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
PT3589661T (pt) 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2
WO2018158716A1 (en) 2017-03-02 2018-09-07 Cadila Healthcare Limited Novel protein drug conjugate formulation
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
EP3560945A1 (de) 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Verfahren zur reinigung von polypeptiden mit polysorbaten
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体
CA3216098A1 (en) 2021-07-30 2023-02-02 Uwe Reusch Duplexbodies
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20260070986A1 (en) 2021-11-03 2026-03-12 Affimed Gmbh Bispecific cd16a binders
GB202309703D0 (en) 2023-06-27 2023-08-09 Epsilogen Ltd Composition
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5001225A (en) * 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
JP2657113B2 (ja) 1989-10-16 1997-09-24 アムジエン・インコーポレーテツド 幹細胞因子
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0539970B1 (de) * 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
JPH05317084A (ja) * 1991-10-30 1993-12-03 Idemitsu Kosan Co Ltd 抗体産生ヒト由来リンパ球及びヒトモノクローナル抗体の製造方法並びに該方法により作製されたヒトモノクロ−ナル抗体
AU687346B2 (en) * 1992-06-30 1998-02-26 Oncologix, Inc. A combination of anti-erbB-2 monoclonal antibodies and method of using
US5489525A (en) * 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
US5910486A (en) * 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
KR20060079258A (ko) 1996-10-18 2006-07-05 제넨테크, 인크. 항-ＥｒｂＢ２ 항체

Also Published As

Publication number Publication date
US20110189168A1 (en) 2011-08-04
PT1375520E (pt) 2013-11-26
US20020164334A1 (en) 2002-11-07
US7354583B2 (en) 2008-04-08
MX9804358A (es) 1998-09-30
EP0865448B1 (de) 2003-10-08
DK0865448T3 (da) 2004-02-02
AU1278497A (en) 1997-06-27
US5783186A (en) 1998-07-21
IL124689A0 (en) 1998-12-06
AU723492B2 (en) 2000-08-31
CA2236913A1 (en) 1997-06-12
ATE251644T1 (de) 2003-10-15
JP2002502230A (ja) 2002-01-22
PT865448E (pt) 2004-02-27
EP2298816A3 (de) 2014-01-15
EP2298816A2 (de) 2011-03-23
ES2208773T3 (es) 2004-06-16
WO1997020858A1 (en) 1997-06-12
DE69630313T3 (de) 2014-08-14
EP0865448B2 (de) 2014-06-11
SI0865448T2 (sl) 2014-08-29
SI1375520T1 (sl) 2014-01-31
DK0865448T4 (da) 2014-09-15
US6458356B1 (en) 2002-10-01
DK1375520T3 (da) 2014-01-27
EP1375520B1 (de) 2013-10-30
DE69630313T2 (de) 2004-04-29
US8444990B2 (en) 2013-05-21
ES2434917T3 (es) 2013-12-18
US20090142359A1 (en) 2009-06-04
EP1375520A1 (de) 2004-01-02
ES2208773T5 (es) 2014-07-14
EP0865448A1 (de) 1998-09-23
DE69630313D1 (de) 2003-11-13
SI0865448T1 (en) 2003-12-31
US7811566B2 (en) 2010-10-12

Similar Documents

Publication Publication Date Title
IL124689A (en) Apoptosis induced by monoclonal antibody anti-her2
AU545223B2 (en) Hybrid cell line for producing monoclonal antibody
AU4876690A (en) An expression system for production of chimeric monoclonal antibodies
ES2061736T3 (es) Anticuerpos monoclonales contra interleucina-4 humana e hibridomas que los producen.
UA40577C2 (uk) Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
IL86809A (en) Second generation monoclonal antibodies with binding specificity to tag-72, method for detecting human carcinomas utilizing the same, and pharmaceutical compositions containing the same
AU2097692A (en) Method for the production of monoclonal antibodies utilizing a germfree animal
DE3070744D1 (en) Hybrid cell line for producing complement-fixing, monoclonal antibody to human suppressor t cells, antibody, method of preparation of this antibody, diagnostic and therapeutic uses and pharmaceutical compositions comprising this antibody
PH20275A (en) Hybrid cell line for producing monoclonal antibody to a human t cell antigen, antibody and methods
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
AU545181B2 (en) Hybridoma for producing monoclonal antibodies
AU676859B2 (en) Synthetic peptides, antibodies against them and their use
AU545222B2 (en) Hybridoma for producing monoconal antibodies
EP2088158A3 (de) Monoklonaler Antikörper gegen den CCR5 Chemokinrezeptor
EP0357767A4 (en) Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human mucin and with synthetic carbohydrate-carrier conjugates
AU623753B2 (en) Anti-human sperm antibody, and its production
EP0287397A3 (en) Monoclonal antibody specific to human pancreatic phospholipase a2
AU625398B2 (en) Monoclonal antibody recognizing gamma atrial natriuretic polypeptide
CA2065797A1 (en) Monoclonal antibody, polypeptide and production thereof
AU4465489A (en) Monoclonal antibody specifically recognizing n-glycolyl type gm2 hybridoma producing the antibody and method for preparing the hybridoma
EP0332421A3 (en) Monoclonal antibodies recognizing human psti, hybridomas producing the same, and their preparation and use
AU6162794A (en) Carcinoma associated antigen (ng1) monoclonal antibodies against ng1, methods of producing these antibodies and use therefor

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees